TMEM16A inhibitors as a treatment option for cystic fibrosis
Life Sciences, Kardiovaskuläre Erkrankung
- TMEM16A inhibitors represent a causal treatment for cystic fibrosis
- They reduce both excessive mucus formation and airway contraction
- Repurposing possible: TMEM16A inhibitors include FDA-approved and well-tolerated drugs
It is estimated that more than 70 000 patients worldwide are suffering from cystic fibrosis (CF), a lethal genetic disorder characterized by a severe pulmonary disease caused by production a highly viscous and adherent mucus. Because CF is caused by more than 2000 different mutations, a therapy from which all patients would benefit does not exist. An ideal causal therapy for CF would reduce the excessive mucus formation as well as the airway contraction.
Both can be achieved by using compounds that inhibit the calcium-activated chloride channel TMEM16A, which plays a crucial role in both airway smooth muscle contraction and mucus formation. Among such compounds, the FDA-approved and well-tolerated drug niclosamide and related substances have been shown to effectively reduce mucus formation in preclinical animal studies. The drugs may ideally be formulated for inhaled delivery with a spray or nebulizer.
- TMEM16A inhibitors reduce axcessive mucus production as well as airway contraction
- Possible repurposing of FDA-proven and well-tolerated drugs
- Development of a drug formulation for inhalation (in form of a spray or nebulizer)
Efficacy proven in-vivo (mouse asthma model). Seeking partners for further development and licensing